Brainstorm issues 2023 letter to shareholders

New york , dec. 20, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a letter to shareholders. dear shareholders, we remain steadfast in our commitment to advancing nurown as a promising treatment for als patients.
BCLI Ratings Summary
BCLI Quant Ranking